Catalio Capital Management is a multi-strategy investment firm founded in 2020 by George Petrocheilos and R. Jacob Vogelstein. The firm focuses on breakthrough biomedical technology and innovative healthcare companies worldwide, aiming to produce extraordinary returns by creating and sustaining life sciences companies that combine the best science and technology with exceptional management and execution.

Catalio collaborates with an elite group of scientists, engineers, and clinicians—known as Catalio Venture Partners—to identify breakthrough biotechnologies, co-invest with top-tier funds, and recruit top talent from their collective networks.